Overview

Abstract (English)

Objective: The aim of this study was to examine the impact of co-morbid illnesses on treatment outcomes in depressed children and adolescents aged 7-17 who were treated with fluoxetine. Method: This data set was drawn from two large clinical trials involving children and adolescents with depression. Subjects with a diagnosis of major depressive disorder and depressive symptoms of at least moderate severity as defined by a Children’s Depression Rating Score, Revised (CDRS-R) total score =>40 and a Clinical Global Impressions-Severity (CGI-S) rating =>4 were included. Subjects were randomized to receive fluoxetine or placebo over an 8-week period. Predictor analyses examining two primary outcomes were conducted: (1) Response based on Clinical Global Impressions-Improvement (CGI-I) score of 1 or 2, and (2) remission based on CDRS-R score of <=28. Logistic regression models were run to assess whether anxiety disorders were a predictor of response or remission. Result: A total of 309 study participants were included. The only factor found to influence response was treatment with fluoxetine (p=0.022, odds ratio [OR]=2.08, 95% confidence interval [CI] 1.30, 3.31). Several factors were found to influence remission: Treatment with fluoxetine (p<0.0001, OR=3.17, 95% CI 1.80, 5.57), gender (p=0.024, OR=1.90, 95% CI 1.09, 3.30), and number of co-morbid diagnoses (p=0.026, OR 0.73, 95% CI 0.55, 0.96). Conclusion: Anxiety disorders alone did not predict response or remission, but the total number of co-morbid illnesses was associated with remission in depressed children and adolescents treated with fluoxetine.

Abstract (French)

Please note that abstracts only appear in the language of the publication and might not have a translation.